演讲嘉宾
演讲主题 PRESENTATION TOPIC
后PD-1时代新靶点的发现和抗体开发:千鼠万抗计划
沈月雷
董事长兼CEO
百奥赛图
Yuelei Shen
President and CEO
Biocytogen
Dr. Shen received his BS degree from Wuhan University and his PhD in Immunology from the University of Massachusetts Medical School. He has over 25 years of research expertise in multiple disciplines including immunology, molecular biology, and mouse genetics. In 2008, Dr. Shen established Biocytogen Co Ltd, one of the pioneering biotech companies globally developing and producing Genetically Modified (GM) model animals for worldwide academic and pharmaceutical customers. Since then, Biocytogen’s business has expanded rapidly into preclinical services including PK/PD, in vivo efficacy, and toxicology, antibody drug discovery, and industrial scale animal breeding. Currently, Biocytogen’s world-class research and development team, strategically located in Beijing, Jiangsu, and Boston, is comprised of 800 high-achieving scientists, skilled technicians and highly efficient support staff.